Edition:
India

Gilead Sciences Inc (GILD.OQ)

GILD.OQ on NASDAQ Stock Exchange Global Select Market

66.52USD
13 Sep 2019
Change (% chg)

-- (--)
Prev Close
$66.52
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,275,998
52-wk High
$79.61
52-wk Low
$60.32

Latest Key Developments (Source: Significant Developments)

FDA Warns Patients, Health Care Professionals About Rare Instances Of Serious Liver Injury In Some Patients With Advanced Liver Disease
Thursday, 29 Aug 2019 

Aug 28 (Reuters) - Abbvie Inc ::FDA IN BRIEF: FDA WARNS PATIENTS AND HEALTH CARE PROFESSIONALS ABOUT RARE INSTANCES OF SERIOUS LIVER INJURY OR FAILURE WITH CERTAIN HEPATITIS C TREATMENTS IN SOME PATIENTS WITH ADVANCED LIVER DISEASE.FDA - GOT REPORTS THAT USE OF MAVYRET, ZEPATIER, VOSEVI FOR CHRONIC HEPATITIS C RESULTED IN RARE CASES OF WORSENING LIVER FUNCTION, LIVER FAILURE.FDA - HEALTH CARE PROFESSIONALS SHOULD CONTINUE TO PRESCRIBE MAVYRET, ZEPATIER OR VOSEVI AS INDICATED.FDA - HEALTH CARE PROFESSIONALS SHOULD DISCONTINUE USE OF MAVYRET, ZEPATIER OR VOSEVI IN PATIENTS WITH SIGNS AND SYMPTOMS OF WORSENING LIVER FUNCTION.  Full Article

Assembly Biosciences Announces Appointment Of John Mchutchison As President And Chief Executive Officer
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Assembly Biosciences Inc ::ASSEMBLY BIOSCIENCES ANNOUNCES APPOINTMENT OF JOHN MCHUTCHISON, AO, MD, AS PRESIDENT AND CHIEF EXECUTIVE OFFICER.ASSEMBLY BIOSCIENCES - JOHN MCHUTCHISON SUCCEEDS DEREK SMALL, CO-FOUNDER OF CO, WHO WILL CONTINUE AS A BOARD MEMBER AND SENIOR ADVISOR.ASSEMBLY BIOSCIENCES INC - MCHUTCHISON MOST RECENTLY SERVED AS CHIEF SCIENTIFIC OFFICER AND HEAD OF RESEARCH AND DEVELOPMENT AT GILEAD SCIENCES.  Full Article

Ontario Provides Access To Biktarvy For The Treatment Of HIV
Tuesday, 6 Aug 2019 

Aug 6 (Reuters) - Gilead Sciences Inc ::ONTARIO PROVIDES ACCESS TO BIKTARVY® FOR THE TREATMENT OF HIV.GILEAD SCIENCES INC - EFFECTIVE JULY 31, ONTARIO DRUG BENEFIT PROGRAM WILL PROVIDE ELIGIBLE PATIENTS WITH ACCESS TO BIKTARVY.  Full Article

Gilead Sciences Declares Cash Dividend Of $0.63 Per Share Of Common Stock For Q3
Wednesday, 31 Jul 2019 

July 30 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES INC - DECLARED A CASH DIVIDEND OF $0.63 PER SHARE OF COMMON STOCK FOR Q3.  Full Article

Gilead Sciences Posts Q2 EPS Of $1.47
Wednesday, 31 Jul 2019 

July 30 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2019 FINANCIAL RESULTS.QTRLY PRODUCT SALES OF $5.6 BILLION.QTRLY NON-GAAP DILUTED EPS OF $1.82 PER SHARE.QTRLY DILUTED EPS OF $1.47 PER SHARE.QTRLY NON-GAAP DILUTED EPS OF $1.82 PER SHARE.REVISED FULL YEAR 2019 GUIDANCE -.QTRLY TOTAL REVENUES WERE $5.7 BILLION IN 2019 COMPARED TO $5.6 BILLION IN 2018.TOTAL PRODUCT SALES FOR Q2 OF 2019 WERE $5.6 BILLION COMPARED TO $5.5 BILLION FOR SAME PERIOD IN 2018.QTRLY TOTAL REVENUES $5,685 MILLION VERSUS $5,648 MILLION.QTRLY TOTAL REVENUES WERE $5.7 BILLION IN 2019 COMPARED TO $5.6 BILLION IN 2018.NOW SEES 2019 PRODUCT SALES$21,600 MILLION - $22,100 MILLION.HIV PRODUCT SALES WERE $4.0 BILLION FOR Q2 OF 2019 COMPARED TO $3.7 BILLION FOR SAME PERIOD IN 2018.CHRONIC HEPATITIS C VIRUS (HCV) PRODUCT SALES WERE $842 MILLION FOR Q2 OF 2019 COMPARED TO $1.0 BILLION FOR SAME PERIOD IN 2018.Q2 EARNINGS PER SHARE VIEW $1.72, REVENUE VIEW $5.53 BILLION -- REFINITIV IBES DATA.GILEAD - SEES 2019 DILUTED EPS IMPACT OF ACQUISITION-RELATED, UP-FRONT COLLABORATION & LICENSING, STOCK-BASED COMPENSATION & OTHER EXPENSES $3.90 - $4.00 PER SHARE.FY2019 REVENUE VIEW $22.06 BILLION -- REFINITIV IBES DATA.  Full Article

Gilead Sciences Licenses Respiratory, Herpes Antiviral Research Programs From Novartis
Friday, 19 Jul 2019 

July 19 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES LICENSES RESPIRATORY AND HERPES ANTIVIRAL RESEARCH PROGRAMS FROM NOVARTIS.GILEAD SCIENCES INC - GILEAD WILL ACQUIRE EXCLUSIVE GLOBAL RIGHTS TO DEVELOP AND COMMERCIALIZE NOVEL SMALL MOLECULES AGAINST THREE UNDISCLOSED TARGETS.GILEAD-NOVARTIS TO RECEIVE UPFRONT PAYMENT & IS ELIGIBLE TO RECEIVE UP TO $291 MILLION IN MILESTONE PAYMENTS UPON ACHIEVEMENT OF CERTAIN MILESTONES.GILEAD SCIENCES - NOVARTIS IS ALSO ELIGIBLE TO RECEIVE ROYALTIES ON ANNUAL NET SALES UNDER AGREEMENT.  Full Article

Gilead Sciences says Gregg Alton Will Serve As Non-Executive Senior Advisor To Co Through End Of Year
Wednesday, 17 Jul 2019 

July 17 (Reuters) - Gilead Sciences Inc ::GILEAD SCIENCES INC - GREGG ALTON WILL SERVE AS A NON-EXECUTIVE SENIOR ADVISOR TO COMPANY THROUGH END OF YEAR - SEC FILING.GILEAD SCIENCES INC - ALTON WILL RECEIVE A REDUCED BASE SALARY FOR HIS SERVICES.  Full Article

Gilead Appoints Christi L. Shaw As CEO Of Kite
Friday, 12 Jul 2019 

July 11 (Reuters) - Gilead Sciences Inc ::GILEAD APPOINTS CHRISTI L. SHAW AS CHIEF EXECUTIVE OFFICER OF KITE.GILEAD SCIENCES INC - SHAW CURRENTLY SERVES AS SENIOR VICE PRESIDENT OF ELI LILLY &. CO., AND PRESIDENT OF LILLY BIO-MEDICINES.  Full Article

Gilead Announces Intent To Submit New Drug Application For Filgotinib To U.S. FDA This Year
Tuesday, 2 Jul 2019 

July 1 (Reuters) - Gilead Sciences Inc ::GILEAD ANNOUNCES INTENT TO SUBMIT NEW DRUG APPLICATION FOR FILGOTINIB TO U.S. FOOD AND DRUG ADMINISTRATION THIS YEAR.  Full Article

FDA - Eliminating Truvada's Risk Evaluation & Mitigation Strategy Established Under 2012 Approval For Use Of The Drug For Hiv Pre-Exposure Prophylaxis
Tuesday, 2 Jul 2019 

July 1 (Reuters) - U.S. Food and Drug Administration::FDA - ELIMINATING TRUVADA'S RISK EVALUATION & MITIGATION STRATEGY ESTABLISHED UNDER 2012 APPROVAL FOR USE OF THE DRUG FOR HIV PRE-EXPOSURE PROPHYLAXIS.FDA - WITH REMOVAL OF RISK EVALUATION & MITIGATION STRATEGY FOR TRUVADA FOR PREP, DRUG MANUFACTURERS NO LONGER REQUIRED TO GIVE EDUCATIONAL MATERIALS.  Full Article

Photo

FDA flags risks from AbbVie, Gilead, Merck hepatitis C drugs to certain patients

The U.S. Food and Drug Administration said on Wednesday it had identified 63 cases of worsening liver function in certain patients taking hepatitis C medicines made by drugmakers Merck & Co Inc, Gilead Sciences and AbbVie Inc.